Activated growth signaling pathway expression in Ewing sarcoma and clinical outcome

Pediatric Blood and Cancer

Volumn 58, Issue 4, 2012, Pages 532-538

  Mora, Jaume ^a   Rodríguez, Eva ^a   de Torres, Carmen ^a   Cardesa, Teresa ^a   Ríos, José ^b   Hernández, Teresa ^c   Cardesa, Antonio ^d   de Alava, Enrique ^c,e  

^a HOSPITAL SANT JOAN DE DÉU   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c Centro de Investigacion del Cancer   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

AKT mTOR pathway; Ewing sarcoma; IGF1 pathway; Immunohistochemistry profiling; P27 KIP1 cell cycle inhibitor

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN P27; S6 KINASE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C RECEPTOR;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; EWING SARCOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; MICROARRAY ANALYSIS; ONCOGENE C KIT; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; SIGNAL TRANSDUCTION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFANT; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PROTEIN KINASES; SARCOMA, EWING; SIGNAL TRANSDUCTION; SURVIVAL RATE;

EID: 84856835709     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23348     Document Type: Article

References (27)

1. Im YH, Kim HT, Lee C, et al. EWS-FLI1, EWS-ERG, and EWS-ETV1 oncoproteins of Ewing tumor family all suppress transcription of transforming growth factor beta type II receptor gene. Cancer Res 2000; 60: 1536-1540.
2. Landuzzi L, De Giovanni C, Nicoletti G, et al. The metastatic ability of Ewing's sarcoma cells is modulated by stem cell factor and by its receptor c-KIT. Am J Pathol 2000; 157: 2123-2131.
3. Ricotti E, Fagioli F, Garelli E, et al. c-kit is expressed in soft tissue sarcoma of neuroectodermic origin and its ligand prevents apoptosis of neoplastic cells. Blood 1998; 91: 2397-2405.
4. Yee D, Favoni RE, Lebovic GS, et al. Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor. J Clin Invest 1990; 86: 1806-1814.
5. Scotlandi K, Benini S, Sarti M, et al. Insulin-like growth factor I receptor-mediated circuit in Ewinǵs sarcoma/peripheral neuroectodermal tumor: A possible therapeutic target. Cancer Res 1996; 56: 4570-4574.
6. Blume-Jensen P, Janknecht R, Hunter T. The c-kit receptor promotes cell survival via activation of PI3′-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser 136. Curr Biol 1998; 8: 779-782.
7. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007; 12: 9-22.
8. Hotfilder M, Lanvers C, Jurgens H, et al. c-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571). Cancer Chemother Pharmacol 2002; 50: 167-169.
9. Gonzalez I, Andreu EJ, Panizo A, et al. Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin induced apoptosis. Clin Cancer Res 2004; 10: 751-761.
10. Merchant MS, Woo CW, Mackall CL, et al. Potential use of imatinib in Ewing's sarcoma: Evidence for in vitro and in vivo activity. J Natl Cancer Inst 2003; 95: 1087-1088.
11. Toretsky JA, Thakar M, Eskenazi AE, et al. Phosphoinositide 3-hydroxide kinase blockade enhaces apoptosis in the Ewing sarcoma family of tumors. Cancer Res 1999; 59: 5745-5750.
12. Mateo-Lozano S, Tirado OM, Notario V. Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferation. Oncogene 2003; 22: 9282-9287.
13. Mora J, de Torres C, Parareda A, et al. Treatment of Ewing sarcoma family of tumors with a modified P6 protocol in children and adolescents. Pediatr Blood Cancer 2011; 57: 69-75.
14. de Alava E, Panizo A, Antonescu CR, et al. Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing's sarcoma. Am J Pathol 2000; 156: 849-855.
15. Prieur A, Tirode F, Cohen P, et al. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol 2004; 24: 7275-7283.
16. Toretsky JA, Kalebic T, Blakesley V, et al. The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem 1997; 272: 30822-30827.
17. Scotlandi K, Avnet S, Benini S, et al. Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells. Int J Cancer 2002; 101: 11-16.
18. Scotlandi K, Maini C, Manara MC, et al. Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells. Cancer Gene Ther 2002; 9: 296-307.
19. Toretsky JA, Steinberg SM, Thakar M, et al. Insulin-like growth factor type 1 (IGF-1) and IGF binding protein-3 in patients with Ewing sarcoma family of tumors. Cancer 2001; 92: 2941-2947.
20. Scotlandi K, Manara MC, Strammiello R, et al. C-kit receptor expression in Ewing's sarcoma: Lack of prognostic value but therapeutic targeting opportunities in appropriate conditions. J Clin Oncol 2003; 21: 1952-1960.
21. Sabatini DM. mTOR and cancer: Insights into a complex relationship. Nat Rev Cancer 2006; 6: 729-734.
22. Chu IM, Hengs L, Slingerland JM. The Cdk inhibitor p27 in human cancer: Prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 2008; 8: 253-267.
23. Matsumoto Y, Tanaka K, Nakatani F, et al. Downregulation and forced expression of EWS-Fli1 fusion gene results in changes in the expression of G(1)regulatory genes. Br J Cancer 2001; 84: 768-775.
24. Matsunobu T, Tanaka K, Matsumoto Y, et al. The prognostic and therapeutic relevance of p27kip1 in Ewing's family tumors. Clin Cancer Res 2004; 10: 1003-1012.
25. Wendel HG, De Stanchina E, Fridman JS, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004; 428: 332-337.
26. Pei H, Li L, Fridley BL, et al. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell 2009; 16: 259-266.
27. Lee M, Theodoropoulou M, Graw J, et al. Levels of p27 sensitize to dual PI3K/mTOR inhibition. Mol Cancer Ther 2011; 10: 1-10.